Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

MarketBeat

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews

Ozempic ingredient linked to dangerous eye condition that could threaten sight

Higher risk of developing nonarteritic anterior ischemic optic neuropathy found in study

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?

Viking Therapeutic may have a GLP-1 blockbuster on their hands with VK2735 as it produces weight loss at 5X the speed of Novo Nordisk's Wegovy GLP-1 drug.

MarketBeat

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

MarketBeat

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

The Independent UK

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

These 3 Stocks Just Announced Major Dividend Hikes

See which three stocks just raised their dividend payments by over 15%. On firm now has a sky-high indicated yield of over 10%.

MarketBeat

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

MarketBeat

Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial

Eli Lilly is still seeing rapid sales growth for its diabetes and weight loss drugs. However, one drug waiting in the wings hopes to be its next blockbuster.

MarketBeat

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

The Guardian - UK

Novo Nordisk CFO says drugmaker focusing on next generation of weight loss drugs

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Fortune

Investors grow anxious at Novo Nordisk's silence over CagriSema weight loss results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Fortune

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

Guitar World

“There was unfinished business. I was hoping to have the opportunity to reclaim my name someday”: Revered luthier Dennis Fano is now leading both Fano and Novo – as his two boutique companies merge

Both firms were founded by Fano, and now they’ve been brought under one leadership structure for the first time

Barchart

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

The Guardian - UK

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

The Times of India

Can Ozempic cause sudden vision loss? A study uncovers the link

A new study has confirmed a link between Novo Nordisk's Ozempic and an increased risk of a rare form of vision loss known as NAION, particularly among diabetes patients. Even more disturbing is the fact that the eye condition is irreversible, untreatable and potentially blinding, which necessitates the need to…

Benzinga

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

Barchart

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

1 … 4 5 6 7

People

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.